BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2025 fourth quarter ...
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and ...
BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has ...
BioLife Solutions, Inc. (BLFS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
In a viral TikTok, a woman alleges that BioLife, a prominent plasma donation center, wrongfully diagnosed her with Hepatitis B, leading to a lifetime ban on donating plasma. The video, posted by Kelly ...
Hosted on MSN
BioLife Solutions raises 2025 revenue guidance to $100M–$103M as cell processing momentum accelerates
CEO Roderick de Greef reported, "We delivered another strong quarter as our team continues to execute and build on the momentum established over the last several quarters." Cell processing revenue ...
BioLife Plasma Services abruptly closed two of its three Wyoming locations Tuesday. Clients, who said they depend on the ...
Merit Medical Systems has acquired US-based Biolife Delaware, a manufacturer of haemostatic devices, in a $120m deal. The transaction value was paid in cash alongside the assumption of Biolife's ...
BOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results